Literature DB >> 2901960

Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

E Perucca1, R Grimaldi, G M Frigo, A Sardi, H Mönig, E E Ohnhaus.   

Abstract

The comparative enzyme inducing effects of rifabutin and the chemically related drug rifampicin have been investigated in 8 normal subjects. Rifampicin 600 mg daily for 7 days caused considerable shortening of the antipyrine half-life and a marked increase in antipyrine clearance, associated with an increased rate of conversion to norantipyrine and, to a lesser extent, 4-hydroxyantipyrine and 3-hydroxymethylantipyrine. The urinary excretion of 6-beta-hydroxycortisol was also markedly increased, while plasma GGT activity showed only a slight albeit statistically significant elevation. In the same subjects, rifabutin in the proposed therapeutic dosage (300 mg daily) for 7 days also enhanced the metabolic elimination of antipyrine, with preferential stimulation of the demethylation pathway, and increased the excretion of 6-beta-hydroxycortisol, but the magnitude of the effects was significantly less than after rifampicin. No significant change in plasma GGT was seen. The results indicate that, contrary to the findings in animals, rifabutin does have enzyme inducing properties in man, although at the dosages assessed they were considerably less than those of rifampicin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901960     DOI: 10.1007/bf00615223

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin.

Authors:  E E Ohnhaus; B Kirchhof; E Peheim
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Letter: Rifampicin and drug metabolism.

Authors:  E K Syvälahti; K K Pihlajamäki; E J Iisalo
Journal:  Lancet       Date:  1974-07-27       Impact factor: 79.321

3.  A kinetic photometric method for serum gamma-glutamyl transpeptidase.

Authors:  G Szasz
Journal:  Clin Chem       Date:  1969-02       Impact factor: 8.327

4.  Activity of ansamycin against Mycobacterium leprae in mice.

Authors:  R C Hastings; R R Jacobson
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

5.  Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo.

Authors:  M W Teunissen; R P Joeres; N P Vermeulen; D D Breimer
Journal:  Xenobiotica       Date:  1983-04       Impact factor: 1.908

6.  HPLC determination of antipyrine metabolites.

Authors:  M Eichelbaum; B Sonntag; H J Dengler
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

7.  Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Authors:  M Danhof; D P Krom; D D Breimer
Journal:  Xenobiotica       Date:  1979-11       Impact factor: 1.908

8.  In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.

Authors:  C L Woodley; J O Kilburn
Journal:  Am Rev Respir Dis       Date:  1982-09

9.  Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

Authors:  M W Teunissen; W Bakker; J E Meerburg-Van der Torren; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

10.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  18 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.

Authors:  C B Trapnell; C Jamis-Dow; R W Klecker; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.

Authors:  Lee C Winchester; Anthony T Podany; Joshua S Baldwin; Brian L Robbins; Courtney V Fletcher
Journal:  J Pharm Biomed Anal       Date:  2014-11-18       Impact factor: 3.935

6.  Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers.

Authors:  J G Gillum; J M Sesler; V L Bruzzese; D S Israel; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients.

Authors:  G Gatti; P Papa; D Torre; M Andreoni; A Poggio; M Bassetti; P Marone
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 9.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.